Estrella Immunopharma
ESLA
16 hedge funds and large institutions have $5.49M invested in Estrella Immunopharma in 2026 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 6 closing their positions.
252% more capital invested
Capital invested by funds: $1.56M → $5.49M (+$3.93M)
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
9.49% more ownership
Funds ownership: 2.65% → 12.14% (+9.5%)
7% more funds holding
Funds holding: 15 → 16 (+1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$4.71M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$304K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$54.8K |
| 4 |
US Bancorp
Minneapolis,
Minnesota
|
+$19.4K |
| 5 |
BlackRock
New York
|
+$15.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$100K |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$87.7K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$77.2K |
| 4 |
Renaissance Technologies
New York
|
-$68.6K |
| 5 |
QC
Quadrature Capital
London,
United Kingdom
|
-$43.3K |
ESLA Hedge Fund Activity: Q1 2026 in Review
16 of the 8,206 institutional investors tracked by Wall St. Rank reported a position in Estrella Immunopharma (ESLA) for Q1 2026, worth a combined $5.49M — up 252% from $1.56M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new ESLA positions and 6 closed out — a net gain of 2 holders — while 3 added to existing stakes and 2 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $4.71M. The largest seller was Citadel Advisors, exiting entirely with an estimated $100K sold.
- 16 institutional investors held Estrella Immunopharma (ESLA) as of Q1 2026, up from 15 in Q4 2025.
- Funds reported $5.49M of Estrella Immunopharma stock for Q1 2026, up 252% quarter-over-quarter.
- 8 funds opened new Estrella Immunopharma positions in Q1 2026 and 6 closed out, a net change of +2 holders.
- The largest Estrella Immunopharma buyer in Q1 2026 was Armistice Capital, an estimated $4.71M added.
- The largest Estrella Immunopharma seller in Q1 2026 was Citadel Advisors, an estimated $100K sold.
Based on aggregated 13F filings for Q1 2026.